UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2018

APTEVO THERAPEUTICS INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware	**001-37746**	**81-1567056**
(State or Other Jurisdiction of Incorporation	**(Commission File Number)**	**(IRS Employer Identification No.)**

2401 4th Avenue, Suite 1050
Seattle, Washington **98121**
(Address of Principal Executive Offices) **(Zip Code)**

Registrant's telephone number, including area code: (206) 838-0500

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item. 7.01. Regulation FD Disclosure.

Aptevo Therapeutics Inc. ("Aptevo") has prepared investor presentation materials with information about Aptevo, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number	Description
99.1	Presentation of Aptevo Therapeutics dated January 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APTEVO THERAPEUTICS INC.

Date: January 8, 2018

By: /s/ Shawnte Mitchell
Shawnte Mitchell, Secretary, Vice President and General Counsel

Exhibit 99.1

January 2018

Aptevo Therapeutics

Investor Presentation

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, product portfolio, product sales, capabilities and any other statements containing the words “believes”, “expects”, “anticipates”, “intends”, “plans”, “forecasts”, “estimates” and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this presentation, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on Aptevo’s business operations, assets or financial results as a result of the separation; a deterioration in the business or prospects of Aptevo; adverse developments in Aptevo’s customer-base or markets; our ability to enter into and maintain selective collaboration and partnership arrangements; the timing of and our ability to achieve milestones in collaboration and partnership contracts; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Annual Report on Form 10-K, as filed on March 31, 2017, and its subsequent reports on Form 10-Q and current reports on Form 8-K

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

Aptevo: At a Glance

Focus	Oncology/Hematology
Commercial Product	IXINITY®
Product Pipeline	Clinical: 2 Preclinical: Multiple
Platform Technology	ADAPTIR™
Employees	~120
Headquarters	Seattle, WA
IXINITY Revenue	2017 (9/30/17) $8.1M 2016 $9.8M 2015 $1.0M
Cash Position	$91M (12/31/2017)



Leading Oncology Platform

- Innovative ADAPTIR platform technology utilizing a novel approach in the highly attractive immuno-oncology field

Leveraging Technology

- Targeted investments in bispecific ADAPTIR therapeutics

Robust IP Estate

- Own and exclusively licensed patents and trade secrets which support our commercial product and pipeline

Aptevo – A Compelling Investment Opportunity

1. Strong leadership with a track record of execution
2. Advancing ADAPTIR to generate novel first-in-class therapeutics
3. Broad pipeline of wholly-owned clinical and preclinical candidates
4. Commercial asset (IXINITY) with growth potential
5. Solid cash position to advance R&D and commercial strategy

Agenda

- **Executing on our Strategy**
- **ADAPTIR – Developing Novel Protein Therapeutics**
- **Impressive Clinical and Preclinical Portfolio**
- **IXINITY – A Growing Commercial Opportunity**
- **Summary**

Experienced Leadership Team

Senior Management

Marvin White – President & CEO
Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA

Jeff Lamothe – SVP, CFO
Former Emergent VP, Finance; Former CFO, Cangene Corporation

Randy Maddux – SVP, Operations
Former VP, Global Mfg & Supply, GSK;
Former VP, Mfg Ops & Quality, Human Genome Sciences

Dr. Scott Stromatt – SVP, CMO
Former Emergent SVP, CMO; Former CMO, Trubion

Dr. Jane Gross – SVP, CSO
Former Emergent VP, Research/Non-Clinical Development; Former VP Immunology Research ZymoGenetics Inc.

Mike Adelman – VP, Commercial Ops.
Former Emergent VP, Commercial Operations; Former, VP Commercial Operations, Cangene Corporation

Shawnte Mitchell – VP, Gen'l Counsel/HR
Former Emergent VP, Associate General Counsel

Board of Directors

Marvin White
Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA

Fuad El-Hibri
Founder, Executive Chairman, Emergent BioSolutions

Daniel Abdun-Nabi
President & CEO, Emergent BioSolutions

Grady Grant, III
Reckitt Benckiser Group (formerly Mead Johnson Nutrition); Eli Lilly & Co.

Zsolt Harsanyi, Ph.D.
N-Gene Research Labs; Exponential Biotherapies; Porton Int'l

Barbara Lopez Kunz
DIA; Battelle; Thermo Fisher Scientific; ICI/Uniqema

John Niederhuber, M.D.
Inova Translational Medicine Institute; NCI; Johns Hopkins Univ.

Deep R&D, Manufacturing, Commercial and Financial Expertise and Experience

Executing on our Strategy to Build Value

Objective	Result

Solidly capitalize Aptevo to advance R&D and commercial programs	• Obtained:
	  • $65M in start-up funding from Emergent
	  • $20M in debt financing from MidCap
	  • $75M commercial asset sale
	• Cash balance: $91M (12/31/2017)

Build proprietary ADAPTIR bispecific platform and rapidly advance candidates towards the clinic	• Advanced APVO414 in Phase 1 development • Positioned APVO436 for Q2:18 IND submission • Positioned APVO210 for Q4:18 IND submission
Demonstrate ADAPTIR versatility by developing ADAPTIR bispecifics with new mechanisms of action (MOA)	• Executed co-development agreement with Alligator Bioscience for 4-1BB x 5T4 immunotherapeutic for solid tumors • Advanced APVO210 with different MOA focusing on targeted cytokine delivery for autoimmune and inflammatory diseases (AIID)
Develop second generation ADAPTIR platform with antibody-like characteristics	• Demonstrated 12.5 day/3.5 day serum half life in rodents/non-human primates (APVO436) • Optimized manufacturing process; able to produce cell culture yields greater than 1.5 g/L; sufficient for clinical and commercial production

Robust and Diversified Product Portfolio

Product/Candidate Target	Technology	Indication	Pre-Clinical	Clinical Development Stage			Marketed	Milestones/Highlights
				Phase I	Phase II	Phase III		
COMMERCIAL PORTFOLIIO								
IXINITY	*Recombinant Protein*	*Hemophilia B*						$8.1M (9/30/17) $9.8M (2016) $1.0M (2015)
ADAPTIR PORTFOLIO								
Otlertuzumab CD37	*ADAPTIR Monospecific*	*PTCL/CLL*						Executing Phase 2 combination study in PTCL
APVO414 CD3/PSMA	*ADAPTIR Bispecific RTCC*	*mCRPC Immuno-oncology*						Executing Phase 1 dose escalation study; Cohort 6
APVO436 CD3/CD123	*ADAPTIR Bispecific RTCC*	*AML*						IND filing Q2 2018
APVO210 IL10/CD86	*ADAPTIR Targeted Cytokine*	*Autoimmune & Inflammatory Diseases*						IND filing Q4 2018
ALG.APV-527* 4-1BB/5T4	*ADAPTIR Bispecific T-cell Co-stimulation*	*Multiple Solid Tumors*						CMC & IND-enabling activities; CTA in 2019
ROR1	*ADAPTIR Bispecific RTCC / New MOA*	*Hematologic and Solid Tumors*						POC in vitro/in vivo; lead candidate in development
Multiple ADAPTIR candidates	*ADAPTIR Bispecific RTCC / New MOA*	*Hematologic and Solid Tumors*						Evaluating RTCC candidates with novel MOA

RTCC – Redirected T-Cell Cytotoxicity = T-Cell Engager

** Partnered with Alligator Bioscience*

Agenda

- Executing On Our Strategy
- ADAPTIR – Developing Novel Protein Therapeutics
- Impressive Clinical and Preclinical Portfolio
- IXINITY – A Growing Commercial Opportunity
- Summary

Advancing ADAPTIR Technology to Generate Novel First-In-Class Therapeutics

- ADAPTIR is Aptevo's platform technology for generating novel monospecific and bispecific antibody therapeutics for immuno-oncology and autoimmune/inflammatory diseases

- ADAPTIR is a robust, flexible platform that can be used to generate bispecific molecules with different mechanisms of action

- The ADAPTIR platform and structure provides distinct advantages over other bispecific technologies and therapeutic approaches

Key Advantages of ADAPTIR Bispecifics*

	ADAPTIR Bispecifics
Unique homodimer structure	✓
Longer half-life	✓
Enhanced stability	✓
Bivalent binding for improved potency	✓
Better manufacturability	✓
Increased flexibility	✓

*Based on current preclinical data for various ADAPTIR candidates

ADAPTIR – A Versatile Therapeutic Platform

Platform produces drugs with multiple mechanisms to stimulate the body's own immune system for the treatment of autoimmune diseases and cancer

T-cell Engagers CD3 + Tumor Antigen	T-cell Co-stimulators + Tumor Antigen (e.g. 4-1BB)	Targeted Cytokines IL-10
		
Oncology	**Oncology**	**AIID/Oncology**

Unique Features of ADAPTIR Bispecific T-Cell Engagers

- Novel, proprietary humanized binding domain targeting CD3
- Increased T-cell engagement and tumor killing compared to monovalent bispecifics
- T-cell stimulation results in reduced cytokine release upon T-cell activation*
- Traditional antibody-like manufacturability and half-life



* MOR209/ES414, A Novel Bispecific Antibody Targeting PSMA For The Treatment of Metastatic Castration-Resistant Prostate Cancer, Hernandez-Hoyos et al. Molecular
Cancer Therapeutics, July 12 2016 DOI: 10.1158/1535-7163.MCT-15-0242

ADAPTIR - More Potent than Heterodimer Bispecifics Targeting Same Antigen

- ADAPTIR RTCC molecules have more potent tumor killing compared to heterodimer formats targeting the same tumor antigen
- Lower concentrations (EC50) needed to achieve same potency in Tumor Lysis Assays



Tumor cell lysis



ADAPTIR RTCC Candidates Induce Lower Levels of Cytokines than Competitor scFv-scFv Formats

ADAPTIR bispecifics generate lower levels of cytokines when tumor antigen present compared to other formats (scFv-scFv) targeting the same tumor antigen



Cytokines measured after 20 hr stimulation of T cells with ADAPTIR and tumor cells

Agenda

- Executing On Our Strategy
- ADAPTIR – Developing Novel Protein Therapeutics
- Impressive Clinical and Preclinical Portfolio
- IXINITY – A Growing Commercial Opportunity
- Summary

ADAPTIR Portfolio Snapshot

Product Candidate	Technology	Indication	Target	Pre-Clinical	Clinical Development Stage			Milestones/Highlights
					Phase I	Phase II	Phase III	
Otlertuzumab	*ADAPTIR Monospecific*	*PTCL/CLL*	*CD37*					Executing Phase 2 combination study in PTCL
APVO414	*ADAPTIR Bispecific RTCC*	*mCRPC*	*CD3/PSMA*					Executing Phase 1 dose escalation clinical trial; Cohort 6
APVO436	*ADAPTIR Bispecific RTCC*	*AML*	*CD3/CD123*					Initiated CMC and IND-enabling activities; IND filing Q2 2018
APVO210	*ADAPTIR Targeted cytokine*	*IBD*	*IL10/CD86*					Initiated CMC and IND-enabling activities; IND filing Q4 2018
ALG.APV-527 *	*ADAPTIR Bispecific T-cell Co-Stimulation*	*Multiple Solid Tumors*	*41BB/Tumor Antigen*					Initiated CMC and IND-Enabling Activities; CTA in 2019
ROR1	ADAPTIR Bispecific RTCC / New MOA	Heme/Onc & Solid Tumors	ROR1					POC in vitro and in vivo; lead candidate in development
ADAPTIR Candidate 1	*RTCC / and New MOA*	*Heme/Onc & Solid Tumors*	*Undisclosed Tumor Antigen*					Evaluating RTCC candidates with novel MOA
ADAPTIR Candidate 2	*RTCC / and New MOA*	*Heme/Onc & Solid Tumors*	*Undisclosed Tumor Antigen*					Evaluating RTCC candidates with novel MOA
ADAPTIR Candidate 3	*RTCC / and New MOA*	*Heme/Onc & Solid Tumors*	*Undisclosed Tumor Antigen*					Evaluating RTCC candidates with novel MOA

RTCC – Redirected T-Cell Cytotoxicity = T-Cell Engager

**Partnered with Alligator Bioscience*

Otlertuzumab – Clinical Candidate

CANDIDATE	 αCD37 scFv Human IgG_1 Fc 
OPPORTUNITY	• ADAPTIR monospecific antibody
FUNCTION/ MOA	• Targets CD37 • Direct apoptosis, antibody-dependent cell cytotoxicity
INDICATIONS	• PTCL - Peripheral T-Cell Lymphoma (PTCL) • CLL – Chronic Lymphocytic Leukemia • NHL – Non-Hodgkin Lymphoma
DEVELOPMENT STAGE	• > 250 subjects treated to date • Clinical POC published in CLL • Demonstrates increased ORR/PFS in CLL in combination with bendamustine • Phase 2 initiated in PTCL
PARTNERSHIP STATUS	• Wholly owned by Aptevo

Otlertuzumab + Bendamustine Significantly Increased Overall Response Rate



Otlertuzumab + Bendamustine Significantly Increased Progression Free Survival



APVO414 – Clinical Candidate

CANDIDATE	 αPSMA αCD3 
OPPORTUNITY	• Bispecific protein therapeutic targeting prostate specific membrane antigen (PSMA) & CD3
FUNCTION/MOA	• Demonstrates redirection of T-cells to kill tumor cells expressing PSMA *in vitro* and *in vivo*
INDICATIONS	• Metastatic castration-resistant prostate cancer (mCRPC)
DEVELOPMENT STAGE	• Open-label Phase 1 continuous infusion study underway (Stage 1) • Objectives: MTD, tolerability, PK, PD, immunogenicity, cytokine response, clinical activity
PARTNERSHIP STATUS	• Wholly owned by Aptevo

APVO414 Phase 1 Dose Escalation for mCRPC

- Currently in Cohort 6
  - Well tolerated; enrollment continues
- Amended study with Continuous Infusion to reduce Anti-Drug Antibody (ADA)
  - Clinical data with other drugs suggests continuous exposure desensitizes immune system and reduces ADA
- Dramatic reduction in ADA with continuous infusion; 1,000 fold reduction
  - Titers reduced from 1:250,000 to 1:350
- Dose escalation ongoing to define MTD
  - Clinical measurements: PSA, tumor size by CT scan, circulating tumor cells
- Data expected end of 2018
- Modified ADAPTIR bispecific platform to eliminate ADA in Next Generation ADAPTIR candidates

APVO436 – Preclinical Candidate

CANDIDATE	 αCD123 scFv αCD3 scFv
OPPORTUNITY	• CD123 x CD3 bispecific candidate
FUNCTION/MOA	• Engages T cell via binding to CD3 to specifically kill tumor cells expressing CD123
INDICATIONS	• Targets multiple hematological malignancies • AML, ALL, hairy cell leukemia, myelodysplastic syndrome
DEVELOPMENT STAGE	• CMC and IND-enabling activities underway • IND Filing Q2:18
PARTNERSHIP STATUS	• Wholly owned by Aptevo

APVO436 Activity with Newly Diagnosed or Relapsed/Refractory AML Patient Samples*

- Addition of healthy donor T cells increased cytotoxicity in a E:T-dependent manner
- Significant cytotoxicity achieved even at the lowest levels of blast CD123 expression
- No consistent linear relationship between the level of blast CD123 expression and cytotoxicity



APVO436 Eliminates Skeletal Tumor Burden in Mice with Established Tumors

- Treatment of established disseminated MOLM-13 tumors in mice with APVO436 resulted in rapid reduction in skeletal tumor burden





- NSG mice implanted IV with MOLM-13 cells on day 0
- T cells implanted on day 4

APVO210 – Preclinical Candidate

CANDIDATE	 αCD86 scFv monomeric IL-10 • Fc mutations • No FcγR binding • No ADCC/CDC • Retains FcRn binding
OPPORTUNITY	• Targeted cytokine based on ADAPTIR platform
FUNCTION/ MOA	• Anti-CD86 scFv delivers IL-10 specifically to antigen presenting (CD86+) cells to suppress inflammation and induce tolerogenic T cells
INDICATIONS	• Autoimmune and inflammatory diseases • Inflammatory bowel disease, transplant, rheumatoid arthritis
DEVELOPMENT STAGE	• In vivo POC established (Graft vs. Host Disease) • Lead candidate selected; CMC and IND enabling studies underway • IND filing Q4:18
PARTNERSHIP STATUS	• Wholly owned by Aptevo

APVO210 Suppresses Inflammation Through a Different Mechanism of Action



- Inhibits monocyte, macrophage, dendritic cell function
  - Inhibits antigen presentation and subsequent T-cell activation
  - Functions below levels required for CD86 saturation
  - 10-100 fold more potent than abatacept in preclinical animal studies
- Inhibits release of pro-inflammatory cytokines by innate immune system
- Induces tolerogenic dendritic cells and T-regulatory Type 1 cells

ALG.APV-527 – Preclinical Candidate

CANDIDATE	 **α4-1BB scFv** **α5T4**
OPPORTUNITY	• Engages T-cells through co-stimulatory receptor 4-1BB
FUNCTION/MOA	• Reactivates antigen-primed T cells to specifically kill tumor cells; Promotes CD8 T-cell survival and effector function
INDICATIONS	• Multiple solid tumor indications: breast, cervical, non-small-cell-lung, prostate, renal, gastric, colorectal and bladder cancers
DEVELOPMENT STAGE	• Lead clinical candidate selected • CMC and IND-enabling studies underway
PARTNERSHIP STATUS	• Joint 50/50 ownership & co-development agreement with Alligator Bioscience

ALG.APV-527 Targeted Immunotherapeutic Bispecific Targeting 41BB x 5T4

- Targeted immunotherapy offers the potential for enhanced efficacy and safety
- Targets 4-1BB (Costimulatory Receptor, member of TNFR super family) and 5T4 Tumor Antigen
- 5T4 expressed on multiple solid tumors: NSCLC, renal, pancreas, prostate, breast CRC, ovarian and cervical cancers
- Targets T cells previously activated by tumor antigen
- Exerts tumor-localized T-cell activation upon 5T4 binding
- Does not stimulate all (resting or naive) T-cells



ROR1 – Preclinical Candidate

CANDIDATE	
OPPORTUNITY	• Novel therapeutic that redirects T cells to kill ROR1-expressing tumor cells
FUNCTION/MOA	• Engages T cell via binding to CD3 to specifically kill tumor cells expressing ROR1
INDICATIONS	• Multiple solid tumor indications; triple-negative breast cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, kidney cancer
DEVELOPMENT STAGE	• POC construct targeting ROR1 and CD3 generated • Demonstrated *in vitro* and *in vivo* POC • Generation of lead candidate in progress
PARTNERSHIP STATUS	• Wholly owned by Aptevo

ROR1 Bispecific - Delays Tumor Growth and Shows 80% Survival in a Xenograft Model





- Statistically significant delay of tumor growth and increase in overall survival in subcutaneous xenograft model
- 80% (8/10) of mice at top dose (3 mg x3) tumor free at study end

- MDA-MB-231 only
- PBS/ vehicle control
- ADAPTIR 3 µg (x3)
- ADAPTIR 1 µg (x3)
- ADAPTIR 0.3 µg (x3)

Agenda

- Executing On Our Strategy
- ADAPTIR – Developing Novel Protein Therapeutics
- Impressive Clinical and Preclinical Portfolio
- IXINITY – A Growing Commercial Opportunity
- Summary

IXINITY – Targeting the Hemophilia B Market with a Unique Strategy

- Intravenous blood coagulation therapy to replace factor IX in individuals with Hemophilia B
- U.S. launch: June 2015
- Strong growth opportunity in US and ROW
- Worldwide rights owned by Aptevo*
  - Opportunity to partner for U.S. and ex-U.S. markets
- Indication: Individuals with hemophilia B ages 12 and older

IXINITY®
coagulation factor IX
(recombinant)

*Certain IP owned by UNC and exclusively licensed to Aptevo

Hemophilia B Market Background

- Hemophilia B affects ~4,000 patients in the United States
- A bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood
- Almost exclusively affects males; women are carriers
- Usually inherited, but 30% are spontaneous mutations
- Classified according to the amount of factor IX in the blood:
  - Mild: 5-30% of normal level of factor
  - Moderate 1-5% of normal
  - Severe <1% of normal
- Causes internal bleeding into joints that can lead to death or long term damage that can be crippling if untreated



Agenda

- Executing On Our Strategy
- ADAPTIR – Developing Novel Protein Therapeutics
- Imprssive Clinical and Preclinical Pipeline
- IXINITY – A Growing Commercial Opportunity
- Summary

Financial Snapshot

Shares Outstanding	21.4M	9/30/2017
Cash	$91M	12/31/2017
Debt	$20M	MidCap Financial
IXINITY Revenue	2017 (9/30/17) 2016 2015	$8.1M $9.8M $1.0M
2018 Cash Burn	$55M - $60M	Estimated cash burn

2018 Milestones

Program	Timeframe
• Commence dosing of otlertuzumab in Phase 2 Peripheral T-Cell Lymphoma (PTCL) clinical trial	Q1 2018
• File IND for APVO436 for Acute Myeloid Leukemia (AML)	Q2 2018
• Complete enrollment of Phase 1 dosing cohorts in APVO414 clinical trial	Q3 2018
• Announce APVO414 Phase 1 dose escalation preliminary clinical data	Q4 2018
• File IND for APVO210 in Autoimmune /Inflammatory Diseases (AIID)	Q4 2018
• Expand application of ADAPTIR-based candidates into new mechanisms of action	Ongoing
• Capture increased market share of Hemophilia B market with expanded U.S. sales of IXINITY	Ongoing
• Continue potential partnering discussions around platform / product candidate opportunities	Ongoing

Aptevo – A Compelling Investment Opportunity

1. Strong leadership with a track record of execution
2. Advancing ADAPTIR™ to generate novel first-in-class therapeutics
3. Broad pipeline of wholly-owned clinical and preclinical candidates
4. Commercial asset (IXINITY) with growth potential
5. Solid cash position to advance R&D and commercial strategy